Genmab Net Cash Flow 2019-2025 | GMAB

Genmab net cash flow for the twelve months ending March 31, 2025 was $-3.264B, a 328.58% decline year-over-year.

  • Genmab annual net cash flow for 2024 was $-0.726B, a 200.56% decline from 2023.
  • Genmab annual net cash flow for 2023 was $0.722B, a 444.92% increase from 2022.
  • Genmab annual net cash flow for 2022 was $0.133B, a 50.91% decline from 2021.

Genmab Net Cash Flow 2019-2025 | GMAB

  • Genmab annual net cash flow for 2024 was $-0.726B, a 200.56% decline from 2023.
  • Genmab annual net cash flow for 2023 was $0.722B, a 444.92% increase from 2022.
  • Genmab annual net cash flow for 2022 was $0.133B, a 50.91% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.5B
Amgen (AMGN)$159.7B
Gilead Sciences (GILD)$139.4B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$96.3B
GSK (GSK)$78.4B
CSL (CSLLY)$77.4B
Regeneron Pharmaceuticals (REGN)$61.6B
Alnylam Pharmaceuticals (ALNY)$41.2B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$20.4B
Biogen (BIIB)$19.5B
Insmed (INSM)$19.3B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$14.2B
Incyte (INCY)$13.5B
Moderna (MRNA)$12.7B
Exelixis (EXEL)$12.4B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.4B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.9B
Regencell Bioscience Holdings (RGC)$7.3B
Legend Biotech (LEGN)$7.2B